Valuation: Verastem, Inc.

Market Cap 76Cr 68Cr 63Cr 57Cr 108.31Cr 7.34TCr 108.75Cr 758.47Cr 297.25Cr 3.74TCr 284.94Cr 278.72Cr 12TCr P/E 2026 *
-5.1x
P/E 2027 * -7.19x
Enterprise Value 80Cr 72Cr 66Cr 61Cr 114.29Cr 7.75TCr 114.75Cr 800.34Cr 313.66Cr 3.95TCr 300.68Cr 294.11Cr 13TCr EV / Sales 2026 *
6.9x
EV / Sales 2027 * 4.21x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
07/10 B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating MT
29/09 Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer CI
18/09 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
17/09 Wolfe Research Initiates Verastem at Outperform MT
14/09 RTW Biotech NAV rises 15% as public investments drive returns AN
08/09 Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers CI
11/08 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
08/08 Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million CI
07/08 Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026
07/08 Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
29/07 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer CI
23/07 Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer CI
07/07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
1 day+3.33%
1 week+8.83%
Current month+4.10%
1 month+9.97%
3 months+51.54%
6 months+57.82%
Current year+8.55%
1 week 7.52
Extreme 7.52
8.58
1 month 7.2
Extreme 7.195
8.64
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Sell

Chief Financial Officer

-2,566 0.0042%
01/10/26 Sell

Chief Executive Officer

-44,121 0.0717%
21/09/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+3.33%+8.83%-2.22%+3.97% 76Cr
-2.59%-5.70%+50.69%+86.86% 7.06TCr
+3.23%-10.67%+6.27%+53.70% 5.1TCr
+1.56%+1.17%+8.49%+31.81% 4.81TCr
+0.39%+0.65%+31.14%+28.97% 4.28TCr
+0.87%-8.17%+293.37%+642.41% 4.07TCr
+1.24%-1.01%+10.74%+100.64% 4.03TCr
-2.13%-1.64%+8.63%+46.88% 3.06TCr
-0.46%-1.28%+42.23%+20.34% 2.82TCr
+5.32%+0.06%-5.00%-12.78% 2.44TCr
Average +1.08%-1.51%+44.43%+100.28% 3.77TCr
Weighted average by Cap. +0.56%-2.92%+51.24%+115.35%

Financials

2026 *2027 *
Net sales 12Cr 10Cr 9.62Cr 8.78Cr 17Cr 1.12TCr 17Cr 115.98Cr 45Cr 572.34Cr 44Cr 43Cr 1.84TCr 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 26Cr 180.31Cr 71Cr 889.8Cr 68Cr 66Cr 2.86TCr
Net income -17Cr -15Cr -14Cr -13Cr -24Cr -1.61TCr -24Cr -166.07Cr -65Cr -819.55Cr -62Cr -61Cr -2.63TCr -16Cr -14Cr -13Cr -12Cr -23Cr -1.53TCr -23Cr -157.61Cr -62Cr -777.8Cr -59Cr -58Cr -2.5TCr
Net Debt 4.19Cr 3.75Cr 3.47Cr 3.17Cr 5.98Cr 405.51Cr 6Cr 42Cr 16Cr 206.65Cr 16Cr 15Cr 663.12Cr -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
09/26/09 $8.380 +3.33% 29,70,338
08/26/08 $8.110 -1.88% 30,51,551
07/26/07 $8.265 +6.65% 39,28,558
06/26/06 $7.750 -3.12% 25,13,883
05/26/05 $8.000 +3.90% 22,17,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.380USD
Average target price
15.00USD
Spread / Average Target
+79.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock